Orally administered 50 mg/kg rofecoxib, another selective COX-2 inhibitor, predictably decreased the incidence of liver metastasis in BALB/c mice carrying implanted MC-26 murine colon cancer cells in their splenic subcapsule. This evidence concerns the gene PTGS2 and colonic neoplasm.